Type 1 interferons as a potential treatment against COVID-19

Erwan Sallard; François-Xavier Lescure; Yazdan Yazdanpanah; France Mentre; Nathan Peiffer-Smadja

doi:10.1016/j.antiviral.2020.104791

Type 1 interferons as a potential treatment against COVID-19

Antiviral Res. 2020 Jun:178:104791. doi: 10.1016/j.antiviral.2020.104791. Epub 2020 Apr 7.

Authors

Erwan Sallard¹, François-Xavier Lescure², Yazdan Yazdanpanah², France Mentre³, Nathan Peiffer-Smadja⁴

Affiliations

¹ École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris, France.
² Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.
³ Université de Paris, IAME, INSERM, F-75018, Paris, France.
⁴ Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France. Electronic address: nathan.peiffer-smadja@inserm.fr.

Abstract

Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.

Keywords: COVID-19; Interferon; SARS-CoV-2.

MeSH terms

Antiviral Agents / therapeutic use*
Betacoronavirus / isolation & purification
COVID-19
Coronavirus Infections / drug therapy*
Coronavirus Infections / virology
Humans
Interferon Type I / therapeutic use*
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / virology
SARS-CoV-2

Substances

Antiviral Agents
Interferon Type I